Related Experiment Video
Updated: Jul 18, 2026
08:43
An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
Published on: July 28, 2012
Application of antisense technology to urologic cancers
1Department of Urology, Niigata University Faculty of Medicine, Asahimachi, Niigata, Japan. ytomita@med.niigata-u.ac.jp
Molecular Urology
|May 15, 2002
Summary
Antisense oligodeoxynucleotides (ODNs) offer a promising therapeutic approach by inhibiting target gene expression for diseases like cancer. Further advancements in ODN technology and delivery systems are crucial for realizing their full potential.
Area of Science:
- Molecular Biology
- Genetics
- Pharmacology
Background:
- Antisense oligodeoxynucleotides (ODNs) are short nucleic acid sequences designed to bind to specific messenger RNA (mRNA) molecules.
- This binding inhibits protein synthesis, thereby modulating gene expression.
- ODNs have shown potential in treating various conditions, including malignancies.
Purpose of the Study:
- To review the therapeutic potential of antisense oligodeoxynucleotides (ODNs).
- To highlight the applications of ODNs in human diseases, particularly cancer.
- To identify areas for future development in ODN technology and delivery.
Main Methods:
- Literature review of existing studies on antisense ODNs.
- Analysis of the mechanisms of action for ODN-based gene silencing.
- Evaluation of current challenges and future prospects for ODN therapeutics.
Main Results:
- Antisense ODNs effectively inhibit target gene expression.
- ODNs are applicable to the treatment of human diseases, notably malignancies.
- Significant improvements in ODN design and cellular delivery systems are required.
Conclusions:
- Antisense ODNs represent a promising new class of therapeutic agents.
- Continued research and development are necessary to overcome current limitations.
- ODN-based therapies hold substantial promise for future clinical applications.
Related Concept Videos
01:23RNA Interference
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
02:30siRNA - Small Interfering RNAs
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
02:15Experimental RNAi
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...